AMGN
Price
$333.96
Change
+$2.47 (+0.75%)
Updated
Dec 24 closing price
Capitalization
179.83B
40 days until earnings call
Intraday BUY SELL Signals
PFE
Price
$25.03
Change
+$0.15 (+0.60%)
Updated
Dec 24 closing price
Capitalization
142.31B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMGN vs PFE

Header iconAMGN vs PFE Comparison
Open Charts AMGN vs PFEBanner chart's image
Amgen
Price$333.96
Change+$2.47 (+0.75%)
Volume$833.66K
Capitalization179.83B
Pfizer
Price$25.03
Change+$0.15 (+0.60%)
Volume$19.33M
Capitalization142.31B
AMGN vs PFE Comparison Chart in %
View a ticker or compare two or three
VS
AMGN vs. PFE commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (AMGN: $333.96 vs. PFE: $25.03)
Brand notoriety: AMGN and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 29% vs. PFE: 27%
Market capitalization -- AMGN: $179.83B vs. PFE: $142.31B
AMGN [@Pharmaceuticals: Major] is valued at $179.83B. PFE’s [@Pharmaceuticals: Major] market capitalization is $142.31B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $963.92B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $104.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 0 green FA rating(s).

  • AMGN’s FA Score: 3 green, 2 red.
  • PFE’s FA Score: 0 green, 5 red.
According to our system of comparison, AMGN is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 3 bearish.
  • PFE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AMGN is a better buy in the short-term than PFE.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а +2.44% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.05%. For the same industry, the average monthly price growth was +2.64%, and the average quarterly price growth was +14.79%.

Reported Earning Dates

AMGN is expected to report earnings on Feb 03, 2026.

PFE is expected to report earnings on Feb 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+2.05% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($180B) has a higher market cap than PFE($142B). AMGN has higher P/E ratio than PFE: AMGN (25.83) vs PFE (14.55). AMGN YTD gains are higher at: 32.043 vs. PFE (1.173). PFE has higher annual earnings (EBITDA): 18.5B vs. AMGN (16.5B). PFE has more cash in the bank: 15B vs. AMGN (9.45B). AMGN has less debt than PFE: AMGN (54.6B) vs PFE (60.8B). PFE has higher revenues than AMGN: PFE (62.8B) vs AMGN (36B).
AMGNPFEAMGN / PFE
Capitalization180B142B127%
EBITDA16.5B18.5B89%
Gain YTD32.0431.1732,733%
P/E Ratio25.8314.55177%
Revenue36B62.8B57%
Total Cash9.45B15B63%
Total Debt54.6B60.8B90%
FUNDAMENTALS RATINGS
AMGN vs PFE: Fundamental Ratings
AMGN
PFE
OUTLOOK RATING
1..100
1813
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
34
Fair valued
PROFIT vs RISK RATING
1..100
24100
SMR RATING
1..100
1468
PRICE GROWTH RATING
1..100
4754
P/E GROWTH RATING
1..100
7896
SEASONALITY SCORE
1..100
2250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (16) in the Biotechnology industry is in the same range as PFE (34) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.

AMGN's Profit vs Risk Rating (24) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.

AMGN's SMR Rating (14) in the Biotechnology industry is somewhat better than the same rating for PFE (68) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than PFE’s over the last 12 months.

AMGN's Price Growth Rating (47) in the Biotechnology industry is in the same range as PFE (54) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.

AMGN's P/E Growth Rating (78) in the Biotechnology industry is in the same range as PFE (96) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNPFE
RSI
ODDS (%)
Bearish Trend 2 days ago
60%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
44%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 4 days ago
57%
Declines
ODDS (%)
Bearish Trend 8 days ago
51%
Bearish Trend 9 days ago
58%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
50%
Aroon
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
55%
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signal:
Gain/Loss:
PFE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UDOW60.370.82
+1.38%
ProShares UltraPro Dow30
XLC118.090.70
+0.60%
State Street® CommServSelSectSPDR®ETF
SMHX38.77N/A
N/A
VanEck Fabless Semiconductor ETF
EFNL47.56-0.02
-0.04%
iShares MSCI Finland ETF
SDOW30.65-0.95
-3.01%
ProShares UltraPro Short Dow30

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+0.75%
PFE - AMGN
63%
Loosely correlated
+0.60%
BMY - AMGN
57%
Loosely correlated
+0.79%
ABBV - AMGN
56%
Loosely correlated
+0.48%
NVS - AMGN
55%
Loosely correlated
-0.18%
MRK - AMGN
55%
Loosely correlated
+1.34%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been closely correlated with BIIB. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if PFE jumps, then BIIB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+0.60%
BIIB - PFE
69%
Closely correlated
+0.86%
BMY - PFE
68%
Closely correlated
+0.79%
AMGN - PFE
64%
Loosely correlated
+0.75%
ABBV - PFE
62%
Loosely correlated
+0.48%
NVS - PFE
59%
Loosely correlated
-0.18%
More